New prognostic and predictive factors in advanced colorectal cancer;Nuevos factores pronósticos y predictivos en el cáncer colorrectal avanzado

Medicina Clinica

Volumn 126, Issue 14, 2006, Pages 541-548

  Gil Bazo, Ignacio ^a,b   Páramo, José Antonio ^a   García Foncillas, Jesús ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Angiogenesis; Colorrectal cancer; Hemostasis; Prognosis; Survival

Indexed keywords

D DIMER; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; BLOOD CLOTTING; CHEMOTHERAPY; COLORECTAL CANCER; FIBRINOLYSIS; GASTROINTESTINAL TUMOR; HEMOSTASIS; HUMAN; MEDICINE; PROGNOSIS; REVIEW; THROMBOCYTE; THROMBOEMBOLISM; VASCULAR ENDOTHELIUM;

EID: 33646778489     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13087141     Document Type: Article

References (87)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Skibber J, Minsky B, Hoff P. Cancers of the gastrointestinal tract. Cancer of the colon. En: De Vita V, Hellman S, Rosenberg S, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott Williams and Williams; 2001. p. 1216-95.
3. Martínez-García C, Peris-Bonet R, Sánchez- Pérez M. Epidemiología descriptiva del cáncer en España. En: FESEO, editor. Libro blanco de oncología en España. Madrid: Ergon; 2002.
4. Allende T, García Muñiz JL, Vizoso F, Del Casar JM, Raigoso P, Llana B, et al. Niveles séricos preoperatorios del CEA y pronóstico en el cáncer colorrectal. Rev Esp Med Nucl. 2001;20:358-64.
5. Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol. 2002;13:1430-7.
6. Bombski G, Gasiorowska A, Orszulak-Michalak D, Neneman B, Kotynia J, Strzelczyk J, et al. Elevated plasma gastrin, CEA, and CA 19-9 levels decrease after colorectal cancer resection. Int J Colorectal Dis. 2003;18:148-52.
7. Broll R, Erdmann H, Duchrow M, Oevermann E, Schwandner O, Markert U, et al. Vascular endothelial growth factor (VEGF) - a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol. 2001;27:37-42.
8. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88:1739-57.
9. Cubo T, Padilla D, De la Osa G, Palomino T, García M, Pardo R, et al. Valores séricos del factor de crecimiento del endotelio vascular en pacientes con cancer colorrectal y su significación pronóstica. Med Clin (Barc). 2004;122:201-4.
10. De Vita F, Orditura M, Lieto E, Infusino S, Morgillo F, Martinelli E, et al. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer. 2004;100:270-8.
11. Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer. 2003;39:718-27.
12. Hogdall CK, Christensen IJ, Stephens RW, Sorensen S, Norgaard-Pedersen B, Nielsen HJ. Serum tetranectin is an independent prognostic marker in colorectal cancer and weakly correlated with plasma suPAR, plasma PAI-1 and serum CEA. APMIS. 2002;110:630-8.
13. Hyodo I, Doi T, Endo H, Hosokawa Y, Nishikawa Y, Tanimizu M, et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer. 1998;34:2041-5.
14. Reiter W, Stieber P, Reuter C, Nagel D, Lau-Werner U, Pahl H, et al. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res. 1997;17:2935-8.
15. Von Kleist S, Hesse Y, Kananeeh H. Comparative evaluation of four tumor markers, CA 242, CA 19/9, TPA and CEA in carcinomas of the colon. Anticancer Res. 1996;16:2325-31.
16. Werther K, Sorensen S, Christensen IJ, Nielsen HJ. Circulating vascular endothelial growth factor six months after primary surgery as a prognostic marker in patients with colorectal cancer. Acta Oncol. 2003;42:837-45.
17. Yuste AL, Aparicio J, Segura A, López-Tendero P, Gironés R, Pérez-Fidalgo JA, et al. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer. 2003;2:231-4.
18. Kouri M, Pyrhonen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol. 1992;49:78-85.
19. Hanke B, Riedel C, Lampert S, Happich K, Martus P, Parsch H, et al. CEA and CA 19-9 measurement as a monitoring parameter in metastatic colorectal cancer (CRC) under palliative first-line chemotherapy with weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA). Ann Oncol. 2001;12:221-6.
20. Dixon MR, Haukoos JS, Udani SM, Naghi JJ, Arnell TD, Kumar RR, et al. Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg. 2003;138:962-6.
21. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61:253-70.
22. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-4.
23. Koch AE. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum. 1998;41:951-62.
24. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359-64.
25. Powell J. Update on hemangiomas and vascular malformations. Curr Opin Pediatr. 1999;11:457-63.
26. Hanahan D. A flanking attack on cancer. Nat Med. 1998;4:13-4.
27. Gasparini G. The rationale and future potential of angiogenesis inhibitors in neoplasia. Drugs. 1999;58:17-38.
28. Guba M, Seeliger H, Kleespies A, Jauch KW, Bruns C. Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis. 2004;19:510-7.
29. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999;43 Suppl:42-51.
30. Darland DC, D'Amore PA. Blood vessel maturation: vascular development comes of age. J Clin Invest. 1999;103:157-8.
31. Senger DR. Vascular endothelial growth factor/vascular permeability factor. Multiple biological activities for promoting angiogenesis. En: Voest E, D'Amore P, editors. Tumor angiogenesis and microcirculation. New York: Marcel Dekker: 2001. p. 167-84.
32. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W. Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol. 1998;140:947-59.
33. Dvorak HF, Nagy JA, Berse B, Brown LF, Yeo KT, Yeo TK, et al. Vascular permeability factor, fibrin, and the pathogenesis of tumor stroma formation. Ann N Y Acad Sci. 1992;667:101-11.
34. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001;22:201-7.
35. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575-80.
36. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 1994;9:963-9.
37. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev. 2001;21:146-70.
38. Bikfalvi A, Klein S, Pintucci G, Rifkin D. The roles of proteases in angiogenesis. En: Bicknell R, Lewis C, Ferrara N, editors. Tumor angiogenesis. Oxford: Oxford University Press: 1997. p. 115-24.
39. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol. 1998;93:249-52.
40. Lissoni P, Rovelli F, Malugani F, Brivio F, Fumagalli L, Gardani GS. Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers. 2003;18:152-5.
41. Verheul HM, Hoekman K, Luykx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ, et al. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res. 1997;3:2187-90.
42. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res. 2000;6:3147-52.
43. Gil-Bazo I, Catalán V, Alonso A, Rodríguez J, Paramo JA, De la Cámara J, et al. Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clin Transl Oncol. 2005;7:150-5.
44. Gil-Bazo I, Rodríguez J, Catalán V, Alonso A, De la Cámara J, Espinós J, et al. Impact of vascular endothelial growth factor (VEGF), D-dimer (DD) and plasminogen activator inhibitor-1 (PAI-1) levels on clinical outcome in stage IV colorectal cancer (CRC). Ann Oncol. 2004;15 Suppl 3:85.
45. Gil-Bazo I, Rodríguez J, Santisteban M, Alonso A, Catalán V, De la Cámara J, et al. Riesgo de progresión y muerte asociados a los valores de factores ligados a angiogénesis, coagulación y fibrinólisis en pacientes con cancer colorrectal metastático (CCRM) en tratamiento de quimioterapia (QMT). Clin Transl Oncol. 2005;7 Suppl 1:70.
46. Gil-Bazo I, Rodriguez J, Páramo JA, García-Foncillas J. Angiogénesis y cáncer colorrectal: papel predictivo y pronóstico del factor de crecimiento del endotelio vascular. Med Clin (Barc). 2004;123:396-7.
47. Pepper MS, Montesano R, Mandriota SJ, Orci L, Vassalli JD. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein. 1996;49:138-62.
48. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci. 1997;110(Pt 18): 2293-302.
49. Rodríguez Quesada A, Medina Torres MA, Muñoz-Chápuli Oriol R. Angiogénesis. Málaga: Servicio de Publicaciones de la Universidad de Málaga; 2004.
50. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, et al. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med. 1998;4:923-8.
51. Bajou K, Masson V, Gérard RD, Schmitt PM, Albert V, Praus M, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol. 2001;152:777-84.
52. Durand MK, Bodker JS, Christensen A, Dupont DM, Hansen M, Jensen JK, et al. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost. 2004;91:438-49.
53. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, et al. Role of plasminogen activator-plasm in system in tumor angiogenesis. Cell Mol Life Sci. 2003;60:463-73.
54. Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, et al. Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. Exp Cell Res. 2004;294:130-9.
55. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer. 2003;39:981-8.
56. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg. 2002;26:767-71.
57. Montemurro P, Conese M, Altomare DF, Memeo V, Colucci M, Semeraro N. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. Int J Clin Lab Res. 1995;25:195-200.
58. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun. 1991;181:902-6.
59. Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K, Johnsen M. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene. 2003;22:4389-97.
60. Van Duijnhoven EM, Lustermans FA, Van Wersch JW. Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis. 1993;23:168-72.
61. Strojan P, Budihna M, Smid L, Vrhovec I, Skrk J. Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: analysis of their prognostic significance in squamous cell carcinoma of the head and neck. Anticancer Res. 2000;20:3975-81.
62. Cajot JF, Bamat J, Bergonzelli GE, Kruithof EK, Medcalf RL, Testuz J, et al. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. Proc Natl Acad Sci USA. 1990;87:6939-43.
63. García D, Schweigerer L, Medina MA. Modulation of the proteolytic balance plasminogen activator/plasminogen activator inhibitor by enhanced N-myc oncogene expression or application of genistein. Eur J Cancer. 1998;34:1736-40.
64. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, et al. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest. 1995;96:2593-600.
65. Stefansson S, Petitclerc E, Wong MK, McMahon GA, Brooks PC, Lawrence DA. Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem. 2001;276:8135-41.
66. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature. 1996;383:441-3.
67. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, et al. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J. 2002;16:147-54.
68. McMahon GA, Petitclerc E, Stefansson S, Smith E, Wong MK, Westrick RJ, et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem. 2001;276:33964-8.
69. Hanekom GS, Stubbings HM, Kidson SH. The active fraction of plasmatic plasminogen activator inhibitor type 1 as a possible indicator of increased risk for metastatic melanoma. Cancer Detect Prev. 2002;26:50-9.
70. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol. 2003;82:184-93.
71. Nielsen HJ, Pappot H, Christensen IJ, Brunner N, Thorlacius-Ussing O, Moesgaard F, et al. Association between plasma concentrations of plasminogen activator inhibitor-1 and survival in patients with colorectal cancer. BMJ. 1998;316:829-30.
72. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol. 2000;7:617-23.
73. Sier CF, Verspaget HW, Griffioen G, Verheijen JH, Quax PH, Dooijewaard G, et al. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. Gastroenterology. 1991;101:1522-8.
74. Gil-Bazo I, Catalán V, Páramo J, Quero C, Escrivá DR, Pérez-Ochoa A, et al. El factor Von Willebrand como intermediario entre la hemostasia y la angiogénesis de origen tumoral. Rev Med Univ Navarra. 2003;47:22-8.
75. Gil-Bazo I, Páramo Fernández JA, García-Foncillas J. Hemostasia, angiogénesis y cáncer: papel del factor Von Willebrand. Rev Clin Esp. 2003;203:199-201.
76. Damin DC, Rosito MA, Gus P, Roisemberg I, Bandinelli E, Schwartsmann G. Von Willebrand factor in colorectal cancer. Int J Colorectal Dis. 2002;17:42-5.
77. Schwartsmann G, Damin DC, Roisemberg I. Malignant disease and von Willebrand factor. Lancet Oncol. 2001;2:716-7.
78. Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol. 2005;11:2166-70.
79. Gil-Bazo I, Díaz-González JA, Rodríguez J, Cortes J, Calvo E, Páramo JA, et al. The role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence? World J Gastroenterol. 2005;11:6072-3.
80. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today. 1998;28:373-8.
81. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388-94.
82. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88:745-9.
83. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, et al. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101:77-82.
84. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-45.
85. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22:1201-8.
86. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist. 2004;9 Suppl 1:11-8.
87. Verheul HM, Pinedo HM. Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc). 2003;39 Suppl C:81-93.